{
    "clinical_study": {
        "@rank": "80511", 
        "arm_group": [
            {
                "arm_group_label": "BP1.4979 3mg", 
                "arm_group_type": "Experimental", 
                "description": "BP1.4979 3mg during 3 months"
            }, 
            {
                "arm_group_label": "BP1.4979 10mg", 
                "arm_group_type": "Experimental", 
                "description": "BP1.4979 10mg during 3 months"
            }, 
            {
                "arm_group_label": "BP1.4979 15mg", 
                "arm_group_type": "Experimental", 
                "description": "BP1.4979 15mg during 3 months"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo during 3 months"
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical study which aim is to assess in heavy smokers willing to quit smoking the efficacy\n      and the safety profile of BP1.4979 for smoking cessation on the total abstinence measured by\n      subject diary and confirmed by exhaled CO (abstinent < 10 ppm)."
        }, 
        "brief_title": "Efficacy and Safety of BP1.4979 in Smoking Cessation", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Tobacco Addiction", 
        "condition_browse": {
            "mesh_term": "Behavior, Addictive"
        }, 
        "detailed_description": {
            "textblock": "BP1.4979 is a novel compound with promising efficacy on smoker which have been assessed on\n      phase I studies.\n\n      This is a multicenter,randomized, double blind,  placebo controlled, phase IIb trial with\n      parallel group to assess safety and efficacy of BP1.4979 in smoker."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Main inclusion Criteria:\n\n          -  a smoking history of at least 10 years\n\n          -  subject smoking at least 15 cigarettes per day at the time being  and for at least 30\n             days before selection.\n\n          -  having already made at least 2 attempts to stop\n\n          -  with no period of abstinence > 3 months in the previous year\n\n          -  FTND \u2265 7\n\n        Main exclusion Criteria:\n\n          -  any significant psychiatric illness or mood disorder, assessed by the BDI\n\n          -  HAD scale (A + D \u2265 19, the day of the selection and inclusion)\n\n          -  AUDIT \u2265 8\n\n          -  subject smoking cigars or pipes exclusively\n\n          -  subject taking any antismoking medication and/ or  Nicotine Replacement Therapy (NRT)\n             in the previous month."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785147", 
            "org_study_id": "P12-01 / BP1.4979", 
            "secondary_id": "2012-002731-28"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BP1.4979 3mg", 
                    "BP1.4979 10mg", 
                    "BP1.4979 15mg"
                ], 
                "description": "BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.", 
                "intervention_name": "BP1.4979", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Tobacco addition", 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "contact": {
                "last_name": "Henri-Jean AUBIN, MD, Ph.D", 
                "phone": "+33 (0)1 45 59 30 00"
            }, 
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Ile de France", 
                    "zip": "94800"
                }, 
                "name": "H\u00f4pital Paul Brousse"
            }, 
            "investigator": {
                "last_name": "Henri-Jean AUBIN, MD, Ph.D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "Randomized Placebo Controlled Trial Assessing the Efficacy and Safety of BP1.4979 in Smoking Cessation", 
        "overall_contact": {
            "email": "i.lecomte@bioprojet.com", 
            "last_name": "Isabelle Lecomte, M.D.", 
            "phone": "0033 (0)1 47 03 66 33"
        }, 
        "overall_official": {
            "affiliation": "H\u00f4pital Paul Brousse", 
            "last_name": "Henri-Jean AUBIN, MD, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products", 
                "Czech Republic: State Institute for Drug Control"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary measure of efficacy will be 4-week prolonged abstinence from smoking cigarettes at the end of 12-week double-blind treatment phase (i.e. from V3 to V4).\nThe continuous abstinence measured by subject diary and verified by exhaled CO (abstinent < 10 ppm) will define response to the treatment.", 
            "measure": "4-week prolonged abstinence from smoking cigarettes", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785147"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "7-day tobacco Point Prevalence Abstinence (PPA) will be assessed at each visit by analysis of cigarettes consumption using self-report diaries and measurement of exhaled CO", 
                "measure": "7-day tobacco Point Prevalence Abstinence (PPA)", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }, 
            {
                "description": "Assessment of safety thanks to the number and clinical evaluation of the adverse events.", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Vital signs (measurement of heart rate, blood pressure, and body weight) will be assessed at each study visit, thanks to physical examinations (V0 and V4), ECG and laboratory tests (blood chemistry, haematology, urinanalysis tests, prolactin dosage) at screening (V0), after 4-week treatment (V2) and at V4.", 
                "measure": "Vital signs measures", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }
        ], 
        "source": "Bioprojet", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bioprojet", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}